Phenomenome Discoveries Inc. (PDI) is a Saskatoon based human health research company, focusing on the discovery and development of novel disease screening, treatment and health monitoring products. Founded in 2000 and privately owned, PDI uses its patented biomarker discovery platform to discover and develop new biomarkers for cancer and neurodegenerative disorders and has launched therapeutics and diagnostics divisions based on the results of its research. SNNLive spoke with Dayan Goodenowe, Ph.D., President and CEO of Phenomenome Discoveries Inc., a private company, at the Healthcare Media Day 2015 in San Francisco, CA.
Dr. Goodenowe begins with an overview of the company, “We’re a medical biotech company focusing on diagnostics and therapeutics. Our real claim to fame is understanding the biochemical mechanisms of disease and so we’ve been at this for about 14 years now and so the last couple years what’s really been important is that as we’ve developed biomarkers and translating them into therapeutics as well as diagnostics, we have spent a lot of time and energy getting our infrastructure in place, so it’s been you know a couple years since I’ve been here but we’ve been able to develop our manufacturing facility...get regulatory clearance for laboratory business and now we’re getting prepared to submit our first full FDA approved product line in colon cancer and we have Health Canada approval of pancreatic cancer and Alzheimer’s disease diagnostics."
He then explains how Phenomenome’s technology works, “Our lead products are colon and pancreatic, they both work in a very similar way, different biomarkers and the bottom line is what we’ve identified is we, instead of diagnosing the disease we diagnose the individual who gets disease and so disease has two factors: one is risk or susceptibility and two is trigger. So people who have a high susceptibility require a little trigger to get a disease. People that have low susceptibility need a higher trigger and so what we’ve identified is individuals who have a low-level biomarker called PC 594 and if they have low levels, they’re at extremely elevated risk of getting pancreatic cancer and so it turns pancreatic cancer from a low incidence disease to a high incidence disease and so individuals with a deficiency in 594 actually have a risk of pancreatic cancer 3-4 times higher than the average risk.”
He goes into whether the technology is reimbursable or whether it will be in the future, “It will definitely be reimbursable at some point in time...So right now it’s a private pay product in Canada, it’s at 95 dollars a blood test, we’re not talking ridiculous pricing at all...The goal of these products is for population-based monitoring and screening. So it’s priced at a point where literally millions...everyone over the age of 50 should be getting the blood test every two years. So you can’t have a blood test every two years at that large a population and charge a thousand dollars for it, no one is going to reimburse that.” For more information, check out their website: www.Phenomenome.com
© 2017 Stock News Now
Supported by Superior Web Solutions